Loading…

Medical Research Finder

Legal Notice
Privacy
Terms of Use

Gut microbiota / Evidence-based microbiome knowledge (incl. AI chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

meRfi® AI Chat

Nivolumab

Welcome to meRfi-GM!

Please register to continue your trial period!

meRfi-GM provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

(Login)

Navigation

Nivolumab - a genetically engineered, fully human IgG4 mAb against the negative immunoregulatory human cell surface receptor CD279 (Programmed cell death protein 1 (PD-1), a negative regulatory checkpoint in the T cells.
Gomes et al. 2018 Future Oncology 14: 1241–1252

…

References (Sources)

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
Ferris et al. 2016
Nivolumab in melanoma
Specenier 2016 Exp Rev Anticancer Ther 16(12): 1247-1261
Review
Nivolumab: targeting PD-1 to bolster antitumor immunity
Brahmer et al., 2015
Review
Phase I/II study of metastatic melanoma patients treated with nivolumab who had progressed after ipilimumab
Weber et al. 2016
Safety, Efﬁcacy, and Biomarkers of Nivolumab With Vaccine in Ipilimumab-Refractory or -Naive Melanoma
Weber et al., 2013
The role of checkpoint inhibitors immunotherapy in advanced non-small cell lung cancer in the elderly
Sgambato et al. 2017
Review
Two-year overall survival rates from a randomised phase 2 trial evaluating the combination of nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma
Hodi et al. 2016

AI Chat

5/29/2026

Chat with our artificial intelligence:

Start chat!

Nivolumab

Welcome to meRfi-GM!

Navigation

Contents

References (Sources)

AI Chat

Links